{"source_content":"1证券研究报告作者：行业评级：上次评级：行业报告|请务必阅读正文之后的信息披露和免责申明医药生物强于大市强于大市维持2021年01月13日（评级）分析师潘海洋SAC执业证书编号：S1110517080006分析师郑薇SAC执业证书编号：S11105171100032020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异行业专题研究摘要请务必阅读正文之后的信息披露和免责申明新冠疫情凸显行业重要地位，国外疫情持续带来较强白蛋白提价预期2019年底以来的新冠疫情，带来了对静丙等治疗性血液制品的大量需求，对恢复期血浆以及静丙、白蛋白等治疗性血制品的宣传，有利于教育医生和民众认识血制品；同时，在新冠这类重大公众卫生事件发生时，血制品及恢复性血浆起到了一定治疗作用，体现出血液制品的重要地位及资源稀缺属性，随着国外疫情持续，进口白蛋白企业采浆受限，进口白蛋白可能减少，加之疫情期间国内采浆量的减少，使得后续白蛋白供应可能下降，国产白蛋白有较强提价预期。2020整体批签发增加，Q4国产白蛋白占比有所下降从2020批签发量上来看，静丙受到疫情影响需求增加，批签发同比12%，其他产品同比也有较大增加，其中白蛋白同比增加16%，其中进口白蛋白同比约增长25%，国产白蛋白同比约增长3%，第四季度国产占比由Q3的43%下降至32%；特免类整体批签发量较去年同期有所下降，其中狂免批签发量同比下降4%，破免批签发量同比下降1%，乙免批签发量同比上升8%；因子类：因子Ⅷ同比增长21%，PCC同比增长58%，纤原批签发同比增长59%。建议关注浆量持续提升、产品齐全的血制品企业短期看，受到疫情影响血制品企业业绩增长有限，但从长期来看，血制品高壁垒，行业具有战略意义，供给端弹性有限，企业通过持续进行渠道建设、营销和学术推广，拉动终端纯销需求的增长。建议关注浆量有望持续提升、产品齐全、学术推广强、渠道能力优秀的血制品企业，继续推荐天坛生物、华兰生物、博雅生物，建议关注双林生物/卫光生物。风险提示：行业黑天鹅事件；新品种研发进展低于预期；政策变化风险；企业经营质量管理风险23代码名称2021-01-11评级2019A2020E2021E2022E2019A2020E2021E2022E600161.SH天坛生物46.15买入0.490.540.640.7694.1885.4672.1160.72002007.SZ华兰生物49.95买入0.700.871.081.3071.3657.4146.2538.42300294.SZ博雅生物34.12买入0.981.061.251.4834.8232.1927.3023.05重点标的推荐股票股票收盘价投资EPS(元)P/E请务必阅读正文之后的信息披露和免责申明摘要总览：2020年批签发量整体稳健增长，因子类产品表现优异资料来源：中检院及各所，天风证券研究所整理4表：2020年血制品批签发量2020血制品批签发整体同比表现稳健，从具体品种来看：➢白蛋白：2020批签发约6046.3万瓶，同比提升16%，其中进口白蛋白批签发约3912.7万瓶，同比增长约25%，批签发占比65%，国产白蛋白批签发约2133.7万瓶，同比增长约3%，批签发占比35%；➢免疫球蛋白：大品种：2020年共批签发静丙1279.16万瓶，同比增长12%，狂免近1182.01万瓶，同比下降4%，破免601.74万瓶，同比下降1%；乙免：2020年批签发约112.11万瓶，同比8%。➢因子类：因子Ⅷ2020年批签发约207.22万瓶，同比大幅增长21%，PCC批签发约154.94万瓶，同比增长58%，纤原批签发批签发138.70万瓶，同比增长59%。标准规格，万瓶2017年2018年2019年2020年2020YOY2020Q42020Q4环比同比冻干静注人免疫球蛋白（pH4）16.4818.2925.4742.4467%-36%-8%冻干静注乙型肝炎人免疫球蛋白（pH4）1.181.522.542.665%静注人免疫球蛋白（pH4）1041.571068.351147.141279.1612%-4%8%静注乙型肝炎人免疫球蛋白（pH4）3.233.902.473.4640%2%-7%狂犬病人免疫球蛋白554.30828.561237.491182.01-4%29%12%破伤风人免疫球蛋白450.57338.27606.13601.74-1%79%36%人免疫球蛋白97.9663.96126.31192.5052%162%5%人凝血酶原复合物106.79101.7898.35154.9458%65%109%人凝血因子Ⅷ129.19174.04170.94207.2221%-37%-25%人纤维蛋白原94.1388.8987.10138.7059%196%196%人血白蛋白4071.014816.755212.976046.3016%7%11%乙型肝炎人免疫球蛋白139.68157.23103.84112.118%43%-4%人血白蛋白：2020年批签发同比增加16%，国产占比下滑5图：白蛋白批签发变化（万瓶）图：国产和进口白蛋白占比变化资料来源：中检院及各所，天风证券研究所整理➢2020年批签发约6046.30万瓶，同比提升16%，其中进口白蛋白批签发约3912.65万瓶，同比提升约25%，批签发占比65%，国产白蛋白批签发约2133.65万瓶，同比提升约3%，批签发占比35%。➢2020白蛋白批签发同比增加约833万瓶，其中进口白蛋白增加约778万瓶，占增加值约93%，进口白蛋白仍旧占白蛋白批签发的大多数。国产白蛋白增加约55万瓶，占增加值约7%，进口/国产批签发比由2019年的约60:40增加到近65:35。➢单看2020Q4批签发约1491.2万瓶，环比+7%，其中国产473.3万瓶，环比-22%，占比32%，进口1017.9万瓶，环比增长29%，占比68%。4071.014816.755212.976046.300%2%4%6%8%10%12%14%16%18%20%010002000300040005000600070002017年2018年2019年2020年人血白蛋白YOY0%20%40%60%80%100%120%2017201820192020国产企业进口企业6资料来源：中检院及各所，天风证券研究所整理➢国内上市企业中：天坛、泰邦、莱士和华兰在2020年白蛋白批签发份额最大，占比分比为天坛生物（7.3%）、上海莱士（5.2%）、泰邦生物（5.0%）和华兰生物（4.1%）。➢从白蛋白批签发绝对值来看，天坛生物批签发占比最高，其次为上海莱士、邦泰生物、华兰生物、远大蜀阳和博雅生物。图：主要企业批签发量变化（万瓶）人血白蛋白：国产大份额公司占比维持相对稳定325.23355.41426.24443.310%5%10%15%20%25%01002003004005002017年2018年2019年2020年天坛生物YOY214.16237.20262.15315.320%5%10%15%20%25%0501001502002503003502017年2018年2019年2020年上海莱士YOY308.53297.13366.19300.16-30%-20%-10%0%10%20%30%0501001502002503003504002017年2018年2019年2020年泰邦生物YOY235.35252.94232.89249.91-10%-5%0%5%10%0501001502002503002017年2018年2019年2020年华兰生物YOY165.11173.81158.20184.57-15%-10%-5%0%5%10%15%20%0501001502002017年2018年2019年2020年远大蜀阳YOY52.1986.2584.4586.57-10%0%10%20%30%40%50%60%70%0204060801002017年2018年2019年2020年博雅生物YOY静注人免疫球蛋白：2020年度批签发同比提升12%7图：2017-2020年批签发变化（万瓶）图：2020年各企业批签发量资料来源：中检院及各所，天风证券研究所整理➢2020年批签发1279.16万瓶，同比增长12%。2020年第四季度批签发276.66万瓶，同比增长8%，环比下降4%。➢2020年共有15个企业有批签发（上市公司中合并母公司+控股子公司），其中批签发较多的企业有：天坛生物（占比25%）、上海莱士（占比16%）、泰邦生物（占比13%）、华兰生物（占比10%）、远大蜀阳（占比7%）。0%2%4%6%8%10%12%14%02004006008001,0001,2001,4002017年2018年2019年2020年静注人免疫球蛋白（pH4）YOY3%10%1%4%3%16%5%13%25%6%1%7%哈尔滨派斯菲科华兰生物绿十字（中国）南岳生物山西康宝上海莱士双林生物泰邦生物天坛生物卫光生物新疆德源远大蜀阳8资料来源：中检院及各所，天风证券研究所整理➢2020年，天坛、莱士和泰邦静丙批签发份额最大，莱士、派斯菲科、博雅在批签发同比增速方面脱颖而出。批签发占比较大的公司有：天坛生物（316万，同比增长13%）、上海莱士（205万，同比增长52%）、泰邦生物（107万，同比下降9%）、华兰生物（131万，同比下降6%）、远大蜀阳（95万，同比下降6%）、卫光生物（77万，同比增长29%）。图：主要企业批签发量变化（万瓶）静注人免疫球蛋白：天坛、泰邦排名靠前，卫光生物增速亮眼0%5%10%15%20%25%0501001502002503003502017年2018年2019年2020年天坛生物YOY-10%0%10%20%30%40%50%60%0501001502002502017年2018年2019年2020年上海莱士YOY-10%-5%0%5%10%0501001502002017年2018年2019年2020年泰邦生物YOY-40%-30%-20%-10%0%10%20%30%0501001502002017年2018年2019年2020年华兰生物YOY-30%-20%-10%0%10%20%30%0204060801001202017年2018年2019年2020年远大蜀阳YOY0%5%10%15%20%25%30%35%0204060801002017年2018年2019年2020年卫光生物YOY狂犬病人免疫球蛋白：2020年批签发下降4%9资料来源：中检院及各所，天风证券研究所整理➢2020年狂免批签发近1182万瓶，同比下降4%，批签发小幅下降。2020年第四季度批签发340万瓶，同比增长12%，环比增长29%。➢2020年狂免批签发份额排名靠前的厂家分别为卫光生物（17%）、远大蜀阳（17%）、泰邦生物（14%）、上海莱士（11%）、双林生物（11%）、华兰生物（10%）、博雅生物（7%），其中卫光生物和博雅生物批签发分别同比增长96%、23%。图：2017-2020年批签发变化（万瓶）图：2020年各企业批签发量占比表：2017-2020年各企业批签发量（万瓶）-10%0%10%20%30%40%50%60%02004006008001,0001,2001,4002017年2018年2019年2020年狂犬病人免疫球蛋白YOY17%7%17%5%10%11%14%2%6%11%卫光生物博雅生物远大蜀阳南岳生物华兰生物双林生物泰邦生物博晖创新天坛生物上海莱士标准规格万瓶2017年2018年2019年2020年万瓶合计554.30828.561237.491182.01卫光生物76.5745.29103.83203.43博雅生物9.3645.3465.5780.60远大蜀阳85.31145.10189.88202.74南岳生物43.5648.3459.5457.11华兰生物47.73150.58125.86118.20双林生物135.3744.49143.41134.12泰邦生物106.30109.79179.15162.19上海莱士50.10140.47232.22135.51博晖创新26.3426.1521.37天坛生物64.67111.8966.74中国医药5.24中原瑞德2.91破伤风人免疫球蛋白：批签发小幅下降，远大蜀远、华兰生物或批量具优势10资料来源：中检院及各所，天风证券研究所整理图：2017-2020批签发变化（万瓶）表：2017-2020各企业批签发量（万瓶）➢2020破免批签发602万瓶，同比下降1%，同比小幅下降。2020年第四季度批签发190万瓶，同比增加36%，环比增加79%。➢2020批签发靠前的企业有华兰生物、泰邦生物、天坛生物、远大蜀阳，同比增速分别为增长8%、增长3%、下降31%和增长10%，批签发占比分别为25%、23%、16%和14%。图：2020各企业批签发量占比-40%-20%0%20%40%60%80%100%01002003004005006007002017年2018年2019年2020年破伤风人免疫球蛋白YOY1%25%8%12%23%16%2%14%博晖创新华兰生物上海莱士双林生物泰邦生物天坛生物卫光生物远大蜀阳标准规格2017年2018年2019年2020年万瓶合计450.57338.27606.13601.74华兰生物125.6186.93140.45152.18泰邦生物93.0863.82132.26136.38天坛生物67.3249.85138.8796.21远大蜀阳26.0338.6577.0484.71双林生物80.3142.4342.3272.52上海莱士24.6240.6139.6246.39卫光生物31.985.3525.9411.38博晖创新5.251.98南岳生物10.644.40中原瑞德1.62乙型肝炎人免疫球蛋白：2020批签发同比增长52%11资料来源：中检院及各所，天风证券研究所整理图：2017-2020批签发变化（万瓶）表：2017-2020各企业批签发量（万瓶）图：2020各企业批签发量占比➢2020乙免批签发193万瓶，同比增长52%。2020年第四季度批签发72万瓶，同比增长5%，环比增长162%。➢乙免批签发量较小，与静注乙免、冻干静注乙免在一定程度上可互相代替，在季度上也呈现出多少交替的趋势。2020批签发量由高到低的企业分别为天坛生物、博辉创新、新疆德源、博雅生物（广东）、华兰生物和卫光生物，占比分别为23%、20%、13%、13%、8%和7%，双林生物和博雅生物无批签发。-60%-40%-20%0%20%40%60%80%100%120%0501001502002502017年2018年2019年2020年人免疫球蛋白YOY20%13%6%8%7%2%23%7%13%博晖创新博雅生物（广东）哈尔滨派斯菲科华兰生物上海莱士泰邦生物天坛生物卫光生物新疆德源标准规格2017年2018年2019年2020年万瓶合计97.9663.96126.31192.50博晖创新51.9716.599.9438.65博雅生物8.38博雅生物（广东）25.26哈尔滨派斯菲科10.99华兰生物10.8623.8516.5115.37上海莱士13.7114.3313.52双林生物3.01泰邦生物4.304.64天坛生物43.2745.09卫光生物18.2712.4724.5113.53新疆德源25.44远大蜀阳3.148.045.07人凝血因子Ⅷ：整体批签发同比大幅增长21%，莱士批签发提升明显12资料来源：中检院及各所，天风证券研究所整理图：2017-2020批签发变化（万瓶）➢2020人凝血因子Ⅷ批签发207万瓶，同比大幅增长21%。2020年第四季度批签发41万瓶，同比下降25%，环比下降37%。➢2020因子Ⅷ批签发共有5家企业，其中上海莱士大幅增加，各企业批签发量分别为上海莱士71万瓶、华兰生物59万瓶、泰邦生物48万瓶、绿十字中国29万瓶和天坛生物3700件，分别占比34%、29%、23%、14%和0.2%。表：2017-2020各企业批签发量（万瓶）图：2020各企业批签发量占比29%14%34%23%0.2%华兰生物绿十字（中国）上海莱士泰邦生物天坛生物-5%0%5%10%15%20%25%30%35%40%0501001502002502017年2018年2019年2020年人凝血因子ⅧYOY标准规格万瓶2017年2018年2019年2020年人凝血因子Ⅷ129.19174.04170.94207.22华兰生物51.2164.3062.8659.24绿十字（中国）32.4742.1525.9928.95上海莱士19.4124.2338.7670.87泰邦生物24.2340.2643.3347.79天坛生物0.37中国医药1.853.11人凝血酶原复合物：2020同比大幅提升，泰邦、华兰表现亮眼13资料来源：中检院及各所，天风证券研究所整理图：2017-2020批签发变化（万瓶）➢2020年人凝血酶原复合物批签发155万瓶，同比增加58%。2020年第四季度批签发47万瓶，同比增长109%，环比增长65%。➢2020仅有4家企业有PCC批签发，其中泰邦生物85万瓶，同比增长58%，华兰生物61万瓶，同比增长42%，南岳生物2020获批签发8万瓶，博辉创新8100件，批签发占比分别55%、40%、5%和1%。表：2017-2020各企业批签发量（万瓶）图：2020各企业批签发量占比1%40%5%55%博晖创新华兰生物南岳生物泰邦生物-20%-10%0%10%20%30%40%50%60%70%0204060801001201401601802017年2018年2019年2020年人凝血酶原复合物YOY万瓶标准规格万瓶2017年2018年2019年2020年合计106.79101.7898.35154.94博晖创新0.81华兰生物65.3345.3943.0061.23南岳生物7.80泰邦生物33.9941.3353.8685.10天坛生物0.03中国医药7.4415.061.49人纤维蛋白原：莱士批签发大幅增加，贡献主要增量14资料来源：中检院及各所，天风证券研究所整理图：2017-2020批签发变化(万瓶）➢人纤维蛋白原批签发量已经连续4年下降，2020年人纤维蛋白原批签发139万瓶，同比增长59%。2020年第四季度批签发量为57万瓶，同比增长196%，环比增长196%。➢2020年有6家企业有批签发，其中上海莱士增长讯速，各企业中，上海莱士获批人纤维蛋白原50万瓶、哈尔滨派斯菲科32万瓶、博雅生物获批27万瓶、泰邦生物获批22万瓶、绿十字中国6万瓶、卫光生物2万瓶，人纤维蛋白原获批占比分别为36%、16%、20%、23%、4%和2%。表：2017-2020各企业批签发量（万瓶）图：2020各企业批签发量占比20%23%4%36%16%2%博雅生物哈尔滨派斯菲科绿十字（中国）上海莱士泰邦生物卫光生物-20%-10%0%10%20%30%40%50%60%70%0204060801001201401602017年2018年2019年2020年人纤维蛋白原YOY标准规格万瓶2017年2018年2019年2020年合计94.1388.8987.10138.70博雅生物26.1350.7027.3327.20哈尔滨派斯菲科3.8531.56华兰生物7.057.290.24绿十字（中国）6.778.765.78上海莱士48.8812.7511.2949.92泰邦生物11.8029.6022.13天坛生物0.17卫光生物3.202.12中国医药5.136.362.84继续推荐天坛生物、华兰生物、博雅生物，建议关注卫光生物、双林生物15资料来源：中检院及各所，天风证券研究所整理➢头部企业2020静丙批签发同比大幅提升：⚫天坛生物：静丙批签发同比+13%，狂免同比-40%，破免-31%，白蛋白同比+4%；⚫华兰生物：静丙批签发同比-6%，白蛋白同比+7%，破免同比+8%，PCC同比+42%；⚫博雅生物：静丙批签发同比大幅+19%，白蛋白同比+3%，狂免同比+23%；⚫卫光生物：静丙批签发同比+29%，狂免同比+96%，白蛋白同比+38%；⚫双林生物：静丙同比大幅+38%，破免同比+71%，白蛋白同比+8%。表：主要上市企业生物批签发量(万瓶）天坛生物2017年2018年2019年2020年2020YOY冻干静注人免疫球蛋白（pH4）0.411.93374%冻干静注乙型肝炎人免疫球蛋白（pH4）1.181.522.542.665%静注人免疫球蛋白（pH4）231.80279.20280.35316.0713%狂犬病人免疫球蛋白64.67111.8966.74-40%破伤风人免疫球蛋白67.3249.85138.8796.21-31%人免疫球蛋白43.2745.094%人凝血酶原复合物0.03人凝血因子Ⅷ0.37人纤维蛋白原0.17人血白蛋白325.23355.41426.24443.314%乙型肝炎人免疫球蛋白17.5815.9527.3516.45-40%华兰生物2017年2018年2019年2020年2020YOY静注人免疫球蛋白（pH4）153.45110.49139.48131.14-6%狂犬病人免疫球蛋白47.73150.58125.86118.20-6%破伤风人免疫球蛋白125.6186.93140.45152.188%人免疫球蛋白10.8623.8516.5115.37-7%人凝血酶原复合物65.3345.3943.0061.2342%人凝血因子Ⅷ51.2164.3062.8659.24-6%人纤维蛋白原7.057.290.24-100%人血白蛋白235.35252.94232.89249.917%乙型肝炎人免疫球蛋白39.9728.2312.7924.1889%继续推荐天坛生物、华兰生物、博雅生物，建议关注卫光生物、双林生物16资料来源：中检院及各所，天风证券研究所整理续表：主要上市企业生物批签发量（万瓶）博雅生物2017年2018年2019年2020年2020YOY冻干静注人免疫球蛋白（pH4）1.06静注人免疫球蛋白（pH4）36.5467.9054.2664.8419%狂犬病人免疫球蛋白9.3645.3465.5780.6023%人免疫球蛋白8.38人纤维蛋白原26.1350.7027.3327.20-0.5%人血白蛋白52.1986.2584.4586.573%乙型肝炎人免疫球蛋白3.67卫光生物2017年2018年2019年2020年2020YOY冻干静注人免疫球蛋白（pH4）3.450.770.771%静注人免疫球蛋白（pH4）47.3748.2259.6176.9329%狂犬病人免疫球蛋白76.5745.29103.83203.4396%破伤风人免疫球蛋白31.985.3525.9411.38-56%人免疫球蛋白18.2712.4724.5113.53-45%人纤维蛋白原3.202.12-34%人血白蛋白74.2684.4699.47137.0338%乙型肝炎人免疫球蛋白12.0418.606.70双林生物2017年2018年2019年2020年2020YOY静注人免疫球蛋白（pH4）33.8134.0449.7168.8338%狂犬病人免疫球蛋白135.3744.49143.41134.12-6%破伤风人免疫球蛋白80.3142.4342.3272.5271%人免疫球蛋白3.01人血白蛋白85.3184.71109.29118.078%乙型肝炎人免疫球蛋白8.4217✓风险提示：1.行业黑天鹅事件；2.新品种研发进展低于预期；3.政策变化风险；4.企业经营质量管理风险风险提示18郑薇：毕业于中国科学技术大学生物化学与分子专业，曾在中科院广州生物医药与健康研究院做过两年课题。毕业后在深圳迈瑞生物医疗电子股份有限公司（美股退市转A股）就职5年。曾在体外诊断事业部做产品研发2年多，后转至战略发展部任职产品市场经理。2015年离开迈瑞，在华泰证券研究所医药团队任高级研究员，负责医疗器械板块；2016年中加入天风证券，2017年入围新财富；2018年任天风证券医药首席分析师。SAC执业证书编号：S1110517110003。潘海洋：南开大学金融学硕士，天津大学生物工程学士。曾就职于华泰证券研究所，任医药生物行业研究员。目前任天风证券医药行业高级分析师，覆盖大药品领域：中药、生物药、部分化药等，善于从政策层面把握行业发展变化趋势，基本面研究扎实，把握公司拐点变化能力强。SAC执业证书编号：S1110517080006。赵雅韵：西安交通大学化学硕士，制药工程学士，2019年7月加入天风证券，目前主要研究血制品领域。天风医药团队成员简介请务必阅读正文之后的信息披露和免责申明股票投资评级自报告日后的6个月内，相对同期沪深300指数的涨跌幅行业投资评级自报告日后的6个月内，相对同期沪深300指数的涨跌幅买入预期股价相对收益20%以上增持预期股价相对收益10%-20%持有预期股价相对收益-10%-10%卖出预期股价相对收益-10%以下强于大市预期行业指数涨幅5%以上中性预期行业指数涨幅-5%-5%弱于大市预期行业指数涨幅-5%以下投资评级声明类别说明评级体系分析师声明本报告署名分析师在此声明：我们具有中国证券业协会授予的证券投资咨询执业资格或相当的专业胜任能力，本报告所表述的所有观点均准确地反映了我们对标的证券和发行人的个人看法。我们所得报酬的任何部分不曾与，不与，也将不会与本报告中的具体投资建议或观点有直接或间接联系。一般声明除非另有规定，本报告中的所有材料版权均属天风证券股份有限公司（已获中国证监会许可的证券投资咨询业务资格）及其附属机构（以下统称“天风证券”）。未经天风证券事先书面授权，不得以任何方式修改、发送或者复制本报告及其所包含的材料、内容。所有本报告中使用的商标、服务标识及标记均为天风证券的商标、服务标识及标记。本报告是机密的，仅供我们的客户使用，天风证券不因收件人收到本报告而视其为天风证券的客户。本报告中的信息均来源于我们认为可靠的已公开资料，但天风证券对这些信息的准确性及完整性不作任何保证。本报告中的信息、意见等均仅供客户参考，不构成所述证券买卖的出价或征价邀请或要约。该等信息、意见并未考虑到获取本报告人员的具体投资目的、财务状况以及特定需求，在任何时候均不构成对任何人的个人推荐。客户应当对本报告中的信息和意见进行独立评估，并应同时考量各自的投资目的、财务状况和特定需求，必要时就法律、商业、财务、税收等方面咨询专家的意见。对依据或者使用本报告所造成的一切后果，天风证券及/或其关联人员均不承担任何法律责任。本报告所载的意见、评估及预测仅为本报告出具日的观点和判断。该等意见、评估及预测无需通知即可随时更改。过往的表现亦不应作为日后表现的预示和担保。在不同时期，天风证券可能会发出与本报告所载意见、评估及预测不一致的研究报告。天风证券的销售人员、交易人员以及其他专业人士可能会依据不同假设和标准、采用不同的分析方法而口头或书面发表与本报告意见及建议不一致的市场评论和/或交易观点。天风证券没有将此意见及建议向报告所有接收者进行更新的义务。天风证券的资产管理部门、自营部门以及其他投资业务部门可能独立做出与本报告中的意见或建议不一致的投资决策。特别声明在法律许可的情况下，天风证券可能会持有本报告中提及公司所发行的证券并进行交易，也可能为这些公司提供或争取提供投资银行、财务顾问和金融产品等各种金融服务。因此，投资者应当考虑到天风证券及/或其相关人员可能存在影响本报告观点客观性的潜在利益冲突，投资者请勿将本报告视为投资或其他决定的唯一参考依据。19THANKS","data":[{"id":"1","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"白蛋白：2020批签发约6046.3万瓶","content_offset":["1247","1267"],"indicators":[{"indicator_name":"批签发量","indicator_value":["6046.3万瓶","1259","1267"],"indicator_element":{"产品":["白蛋白","1247","1250"],"时间":["2020","1251","1255"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比提升16%","content_offset":["1268","1275"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["16%","1272","1275"],"indicator_element":{"产品":["白蛋白","1247","1250"],"时间":["2020","1207","1211"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"其中进口白蛋白批签发约3912.7万瓶","content_offset":["1276","1295"],"indicators":[{"indicator_name":"批签发量","indicator_value":["3912.7万瓶","1287","1295"],"indicator_element":{"产品":["白蛋白","1280","1283"],"渠道":["进口","1278","1280"],"时间":["2020","1207","1211"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比增长约25%","content_offset":["1296","1304"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["25%","1301","1304"],"indicator_element":{"产品":["白蛋白","1247","1250"],"渠道":["进口","1278","1280"],"时间":["2020","1207","1211"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"批签发占比65%","content_offset":["1305","1313"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["65%","1310","1313"],"indicator_element":{"产品":["白蛋白","1247","1250"],"渠道":["进口","1278","1280"],"时间":["2020","1207","1211"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"国产白蛋白批签发约2133.7万瓶","content_offset":["1314","1331"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2133.7万瓶","1323","1331"],"indicator_element":{"产品":["白蛋白","1316","1319"],"渠道":["国产","1314","1316"],"时间":["2020","1219","1223"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比增长约3%","content_offset":["1332","1339"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["3%","1337","1339"],"indicator_element":{"产品":["白蛋白","1247","1250"],"渠道":["国产","1314","1316"],"时间":["2020","1251","1255"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"批签发占比35%","content_offset":["1340","1348"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["35%","1345","1348"],"indicator_element":{"产品":["白蛋白","1247","1250"],"渠道":["国产","1314","1316"],"时间":["2020","1251","1255"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年共批签发静丙1279.16万瓶","content_offset":["1360","1380"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1279.16万瓶","1371","1380"],"indicator_element":{"产品":["静丙","1369","1371"],"时间":["2020","1360","1364"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比增长12%","content_offset":["1381","1388"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["12%","1385","1388"],"indicator_element":{"产品":["静丙","1369","1371"],"时间":["2020","1360","1364"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"狂免近1182.01万瓶","content_offset":["1389","1401"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1182.01万瓶","1392","1401"],"indicator_element":{"产品":["狂免","1389","1391"],"时间":["2020","1360","1364"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比下降4%","content_offset":["593","599"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降4%","595","599"],"indicator_element":{"产品":["狂免","587","589"],"时间":["2020","907","911"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"破免601.74万瓶","content_offset":["1409","1419"],"indicators":[{"indicator_name":"批签发量","indicator_value":["601.74万瓶","1411","1419"],"indicator_element":{"产品":["破免","1409","1411"],"时间":["2020","1360","1364"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比下降1%","content_offset":["606","612"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降1%","608","612"],"indicator_element":{"产品":["破免","600","602"],"时间":["2020","907","911"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"乙免：2020年批签发约112.11万瓶","content_offset":["1427","1447"],"indicators":[{"indicator_name":"批签发量","indicator_value":["112.11万瓶","1439","1447"],"indicator_element":{"产品":["乙免","1427","1429"],"时间":["2020","1430","1434"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比8%","content_offset":["1448","1452"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["8%","1450","1452"],"indicator_element":{"产品":["乙免","1427","1429"],"时间":["2020","1360","1364"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"因子Ⅷ2020年批签发约207.22万瓶","content_offset":["1458","1478"],"indicators":[{"indicator_name":"批签发量","indicator_value":["207.22万瓶","1470","1478"],"indicator_element":{"产品":["因子Ⅷ","1458","1461"],"时间":["2020","1461","1465"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比大幅增长21%","content_offset":["1479","1488"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["21%","1485","1488"],"indicator_element":{"产品":["因子Ⅷ","1458","1461"],"时间":["2020","1430","1434"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"PCC批签发约154.94万瓶","content_offset":["1489","1504"],"indicators":[{"indicator_name":"批签发量","indicator_value":["154.94万瓶","1496","1504"],"indicator_element":{"产品":["PCC","1489","1492"],"时间":["2020","1430","1434"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比增长58%","content_offset":["644","651"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["58%","648","651"],"indicator_element":{"产品":["PCC","641","644"],"时间":["2020","907","911"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"纤原批签发批签发138.70万瓶","content_offset":["1513","1529"],"indicators":[{"indicator_name":"批签发量","indicator_value":["138.70万瓶","1521","1529"],"indicator_element":{"产品":["纤原批","1513","1516"],"时间":["2020","1430","1434"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比增长59%","content_offset":["657","664"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["59%","661","664"],"indicator_element":{"产品":["纤原批","652","655"],"时间":["2020","907","911"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年批签发约6046.30万瓶","content_offset":["2165","2183"],"indicators":[{"indicator_name":"批签发量","indicator_value":["6046.30万瓶","2174","2183"],"indicator_element":{"产品":["人血白蛋白","2086","2091"],"时间":["2020年","2165","2170"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"其中进口白蛋白批签发约3912.65万瓶","content_offset":["2192","2212"],"indicators":[{"indicator_name":"批签发量","indicator_value":["3912.65万瓶","2203","2212"],"indicator_element":{"产品":["白蛋白","2196","2199"],"渠道":["进口","2194","2196"],"时间":["2020年","2092","2097"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比提升约25%","content_offset":["2213","2221"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["25%","2218","2221"],"indicator_element":{"产品":["白蛋白","2117","2120"],"渠道":["进口","2134","2136"],"时间":["2020年","2165","2170"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"批签发占比65%","content_offset":["1305","1313"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["65%","1310","1313"],"indicator_element":{"产品":["白蛋白","1247","1250"],"渠道":["进口","1278","1280"],"时间":["2020年","1207","1212"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"国产白蛋白批签发约2133.65万瓶","content_offset":["2231","2249"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2133.65万瓶","2240","2249"],"indicator_element":{"产品":["白蛋白","2233","2236"],"渠道":["国产","2231","2233"],"时间":["2020年","2165","2170"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比提升约3%","content_offset":["2250","2257"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["3%","2255","2257"],"indicator_element":{"产品":["白蛋白","2196","2199"],"渠道":["国产","2231","2233"],"时间":["2020年","2165","2170"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年批签发1279.16万瓶","content_offset":["3430","3447"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1279.16万瓶","3438","3447"],"indicator_element":{"时间":["2020年","3430","3435"],"产品":["静注人免疫球蛋白","3347","3355"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年第四季度批签发276.66万瓶","content_offset":["3456","3476"],"indicators":[{"indicator_name":"批签发量","indicator_value":["276.66万瓶","3468","3476"],"indicator_element":{"时间":["2020年第四季度","3456","3465"],"产品":["静注人免疫球蛋白","3665","3673"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比增长8%","content_offset":["3477","3483"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["8%","3481","3483"],"indicator_element":{"时间":["2020年第四季度","3456","3465"],"产品":["静注人免疫球蛋白","3665","3673"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"环比下降4%","content_offset":["3484","3490"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["4%","3488","3490"],"indicator_element":{"时间":["2020年第四季度","3456","3465"],"产品":["静注人免疫球蛋白","3665","3673"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年狂免批签发近1182万瓶","content_offset":["4419","4436"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1182万瓶","4430","4436"],"indicator_element":{"时间":["2020年","4419","4424"],"产品":["狂免","4424","4426"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年第四季度批签发340万瓶","content_offset":["4452","4469"],"indicators":[{"indicator_name":"批签发量","indicator_value":["340万瓶","4464","4469"],"indicator_element":{"时间":["2020年第四季度","4452","4461"],"产品":["狂免","4424","4426"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"环比增长29%","content_offset":["2450","2457"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["29%","2454","2457"],"indicator_element":{"时间":["2020年第四季度","3456","3465"],"产品":["狂免","4424","4426"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020破免批签发602万瓶","content_offset":["5235","5249"],"indicators":[{"indicator_name":"批签发量","indicator_value":["602万瓶","5244","5249"],"indicator_element":{"时间":["2020","5235","5239"],"产品":["破免","5239","5241"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年第四季度批签发190万瓶","content_offset":["5264","5281"],"indicators":[{"indicator_name":"批签发量","indicator_value":["190万瓶","5276","5281"],"indicator_element":{"时间":["2020","5264","5268"],"产品":["破免","5239","5241"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比增加36%","content_offset":["5282","5289"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["36%","5286","5289"],"indicator_element":{"时间":["2020","5199","5203"],"产品":["破免","5239","5241"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"环比增加79%","content_offset":["5290","5297"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["79%","5294","5297"],"indicator_element":{"时间":["2020","5199","5203"],"产品":["破免","5239","5241"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020乙免批签发193万瓶","content_offset":["5897","5911"],"indicators":[{"indicator_name":"批签发量","indicator_value":["193万瓶","5906","5911"],"indicator_element":{"时间":["2020","5897","5901"],"产品":["乙免","5901","5903"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比增长52%","content_offset":["3876","3883"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["52%","3880","3883"],"indicator_element":{"时间":["2020","3786","3790"],"产品":["乙免","5901","5903"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年第四季度批签发72万瓶","content_offset":["5920","5936"],"indicators":[{"indicator_name":"批签发量","indicator_value":["72万瓶","5932","5936"],"indicator_element":{"时间":["2020年第四季度","5920","5929"],"产品":["乙免","5901","5903"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比增长5%","content_offset":["5937","5943"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["5%","5941","5943"],"indicator_element":{"时间":["2020年第四季度","5920","5929"],"产品":["乙免","5901","5903"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"环比增长162%","content_offset":["5944","5952"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["162%","5948","5952"],"indicator_element":{"时间":["2020年第四季度","5920","5929"],"产品":["乙免","5901","5903"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020人凝血因子Ⅷ批签发207万瓶","content_offset":["6546","6564"],"indicators":[{"indicator_name":"批签发量","indicator_value":["207万瓶","6559","6564"],"indicator_element":{"时间":["2020","6546","6550"],"产品":["人凝血因子Ⅷ","6550","6556"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年第四季度批签发41万瓶","content_offset":["6575","6591"],"indicators":[{"indicator_name":"批签发量","indicator_value":["41万瓶","6587","6591"],"indicator_element":{"时间":["2020年第四季度","6575","6584"],"产品":["人凝血因子Ⅷ","6550","6556"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比下降25%","content_offset":["6592","6599"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降25%","6594","6599"],"indicator_element":{"时间":["2020年第四季度","6575","6584"],"产品":["人凝血因子Ⅷ","6550","6556"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"环比下降37%","content_offset":["6600","6607"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["37%","6604","6607"],"indicator_element":{"时间":["2020年第四季度","6575","6584"],"产品":["人凝血因子Ⅷ","6550","6556"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年人凝血酶原复合物批签发155万瓶","content_offset":["7115","7136"],"indicators":[{"indicator_name":"批签发量","indicator_value":["155万瓶","7131","7136"],"indicator_element":{"时间":["2020年","7115","7120"],"产品":["人凝血酶原复合物","7120","7128"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比增加58%","content_offset":["7137","7144"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["58%","7141","7144"],"indicator_element":{"时间":["2020年","7115","7120"],"产品":["人凝血酶原复合物","7042","7050"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年第四季度批签发47万瓶","content_offset":["7145","7161"],"indicators":[{"indicator_name":"批签发量","indicator_value":["47万瓶","7157","7161"],"indicator_element":{"时间":["2020年第四季度","7145","7154"],"产品":["人凝血酶原复合物","7120","7128"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比增长109%","content_offset":["7162","7170"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["109%","7166","7170"],"indicator_element":{"时间":["2020年第四季度","7145","7154"],"产品":["人凝血酶原复合物","7120","7128"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"环比增长65%","content_offset":["7171","7178"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["65%","7175","7178"],"indicator_element":{"时间":["2020年第四季度","7145","7154"],"产品":["人凝血酶原复合物","7120","7128"]},"indicator_supplement":{"属性":""}}]},{"id":"54","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年人纤维蛋白原批签发139万瓶","content_offset":["7658","7677"],"indicators":[{"indicator_name":"批签发量","indicator_value":["139万瓶","7672","7677"],"indicator_element":{"时间":["2020年","7658","7663"],"产品":["人纤维蛋白原","7663","7669"]},"indicator_supplement":{"属性":""}}]},{"id":"55","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"2020年第四季度批签发量为57万瓶","content_offset":["7686","7704"],"indicators":[{"indicator_name":"批签发量","indicator_value":["57万瓶","7700","7704"],"indicator_element":{"时间":["2020年第四季度","7686","7695"],"产品":["人纤维蛋白原","7639","7645"]},"indicator_supplement":{"属性":""}}]},{"id":"56","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"同比增长196%","content_offset":["7705","7713"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["196%","7709","7713"],"indicator_element":{"时间":["2020年第四季度","7686","7695"],"产品":["人纤维蛋白原","7639","7645"]},"indicator_supplement":{"属性":""}}]},{"id":"57","source_document":"2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异.pdf","content":"环比增长196%","content_offset":["7714","7722"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["196%","7718","7722"],"indicator_element":{"时间":["2020年第四季度","7686","7695"],"产品":["人纤维蛋白原","7639","7645"]},"indicator_supplement":{"属性":""}}]}]}